Adagio Medical reports FY2025 net loss $25.1M; FULCRUM-VT trial fully enrolled with 97% acute effectiveness

Adagio Medical Holdings, Inc.

Net loss of $25.1M for FY2025, down from $75.0M in FY2024; Q4 net loss $3.3M vs $57.4M.
Completed enrollment of 209-patient FULCRUM-VT pivotal IDE trial; preliminary 97% acute effectiveness.
Closed private placement with gross proceeds up to $50M; upfront $19M to fund FDA submission.
Cash and equivalents $17.1M as of Dec 31, 2025; no revenue reported.
Appointed former Medtronic executive Sean Salmon to Board; added senior sales and manufacturing VPs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.